Anakuria Therapeutics, Inc

As 2022 draws to a close, an unusually low number of marquee deals have been made in the biopharma sector. But it has been a hectic year nonetheless, with a high volume of deal-making and the lower va

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Amgen, Plexium Team Up Against Challeng